Are BDTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BDTX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Stock Ratings / Health Care / BDTX / insiders

ENGN (34) VYGR (15) LENZ (25) AVXL (32) ⌘ Pro Terminal →

Black Diamond Therapeutics Inc. (BDTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.75 -1.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.74

Black Diamond Therapeutics Inc. (BDTX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $102.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BDTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BDTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.75 (-1.68% 1D, market cap $102.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BDTX ranks #399 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BDTX compare to ENGN and VYGR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BDTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 10.8%. By comparison, ENGN (enGene Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M) and VYGR (Voyager Therapeutics Inc.) posts a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $106.0M). Among the 5-stock peer group, BDTX leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BDTX?

▼

Per BDTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701541), Black Diamond Therapeutics Inc. generated $35.1M in revenue (-84.1% YoY), $22.37B in net income, and $29.6M in free cash flow against $143.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.74 (-0.49%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 84.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BDTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY BDTX SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 84.5% FCF Margin ($29.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.77+2.3% Next Q

Q2 (-2Q)

Grade D$1.81-6.6% Next Q

Q3 (-1Q)

Grade D$1.69+3.6% Next Q

Current

Grade D$1.75-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BDTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BDTX currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.94) and Max Pain ($1.84) forces dealer call-delta covering toward $5.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BDTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BDTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BDTX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BDTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BDTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BDTX)

✓Walkthrough of BDTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BDTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.19%▼ DESCENDING CHANNEL

2026-11-03O $1.86H $1.86L $1.75C $1.75VOL 520.2K

RES: $2.10SUP: $1.40SMA50: $1.94SMA200: $2.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BDTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BDTX Butterfly Map → + Track BDTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-4.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BDTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BDTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BDTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BDTX)

Health Care Rank #399 of 1016 ⚔️ ENGN vs BDTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BDTX vs. ENGN, VYGR, LENZ, AVXL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Black Diamond Therapeutics Inc. (BDTX) ranks #399 by composite RQD confidence (44/100, grade D) and #650 by equity capitalization ($102.3M). Within this direct 5-issuer industry benchmark cohort, BDTX leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BDTX ACTIVE Black Diamond Therapeutics Inc.	D	44/100	—	—	10.8%	-1.68%	$102.3M	Benchmark Subject
ENGN enGene Therapeutics Inc.	E	34/100	—	—	-35.0%	-5.23%	$102.5M	/engn-vs-bdtx →
VYGR Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	+3.49%	$106.0M	/vygr-vs-bdtx →
LENZ LENZ Therapeutics Inc.	E	25/100	—	96.0%	-27.8%	0.00%	$95.8M	/lenz-vs-bdtx →
AVXL Anavex Life Sciences Corp.	E	32/100	—	—	-35.0%	-4.20%	$110.3M	/avxl-vs-bdtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001701541

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Black Diamond Therapeutics Inc. (BDTX) reported GAAP revenue of $35.1M (-84.1% vs. FY2024 revenue of $220.6M , and -85.5% cumulative change since FY2023) , GAAP net income of $22.37B, operating cash flow of $29.6M, and free cash flow of $29.6M (+147.5% YoY). On the balance sheet, BDTX closed FY2025 with $143.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.1M	$22.37B	$29.6M	$29.6M	$143.0M	—
FY2024 (FY)	2024-12-31	$220.6M	-$69.68B	-$62.3M	-$62.3M	$122.6M	—
FY2023 (FY)	2023-12-31	$242.1M	-$82.4M	-$66.7M	-$66.7M	—	—

3. BDTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BDTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BDTX compare to ENGN and VYGR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BDTX?

Where is BDTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BDTX last traded at $1.75 (-1.68% on volume of 494,385 shares), positioning the stock -9.79% below its 50-day simple moving average ($1.94) and -20.09% below its 200-day simple moving average ($2.19). Across its 52-week range of $1.60 to $4.94, BDTX sits at the 4.5% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).

Direct Sub-Reports: BDTX RQD Cockpit BDTX 12M Forecast BDTX Earnings & Move BDTX Dividends & DRIP BDTX Insiders & 13F BDTX Whale Options BDTX Profit Sankey BDTX News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BDTX — Black Diamond Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:51Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

BDTX scores 59 out of 100, a letter grade of C-, with the verdict "Roarable Hold — Cautious Neutral." The five pillars are:

Fundamental Cash Engine: 10 / 20. The rating cites ROIC of 10.8% and an FCF yield of 0%. The reported free cash flow of $29.6M for FY 2025 does not translate into a positive FCF yield in the rating's calculation, which is a point an investor should reconcile before relying on this pillar.
Whale 13F Flow: 12 / 20. The rating labels this pillar as institutional accumulation and options positioning. The holders section contains no 13F data, so the score cannot be traced to specific filings within this source set.
Insider Conviction: 9 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. No Form 4 or PTR records appear in the holders section, so this score is not independently verifiable here.
Macro Regime Fit: 15 / 20. The rating cites a beta of 1.0 and sector sensitivity. This is the strongest pillar, indicating the rating treats the stock's market sensitivity as moderate rather than extreme.
Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.5. These are mid-range readings that support a cautious, not distressed, assessment.

For a prospective investor, the rating's message is that the business is not yet generating clearly positive returns on a cash-yield basis, the balance sheet is serviceable rather than strong, and the stock's risk profile is moderate. The upside case depends on the cash-generation improvement visible in the FY 2025 figures continuing, while the valuation tradeoff is that the company has no reported revenue and a market capitalization of $106.9M, leaving the valuation highly sensitive to near-term cash and operating trajectory. The rating's "Hold" verdict reflects balance between these factors rather than a directional call.

2. Business Model, Unit Margins & SEC Financial Trajectory

Black Diamond Therapeutics Inc. (BDTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company reported — in revenue for each of FY 2023, FY 2024, and FY 2025. Customer base and monetization model are —

Operating income moved from -$86.5M in FY 2023 to -$78.8M in FY 2024 and to $12.5M in FY 2025, and FCF moved from -$66.7M to -$62.3M to $29.6M over the same periods. Gross, operating, and net margins are each reported as 0% in the market data, which is consistent with zero reported revenue. Per the market data, ROIC is 10.8%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. The FY 2025 net income figure of $22.37B is far out of line with the $12.5M operating income and is not explained in the source data; it should be verified against the filing before being relied upon.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: FY 2025 operating income turned positive at $12.5M and free cash flow reached $29.6M, a sharp reversal from prior-year losses. With Fundamental Cash Engine at 10/20 (ROIC 10.8%, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $1.60 – $4.94 52-week range.
🐻 Primary Bear Case: The company reports zero revenue in every period while carrying a $106.9M market cap and an FCF yield of 0%. Investors must weigh current valuation and 6.9x EV/EBITDA against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation partners are therefore — The only sector context available is the classification as Health Care / Biotechnology: Biological Products. An investor should watch for second-order effects from the company's pipeline and partnering arrangements, but none are documented in the source data.

Key Question #1: What clinical, regulatory, or partnering milestones are expected, and when?
Key Question #2: What is the company's debt position, since the debt field is N/A across all periods while Debt/Equity is reported as 0.5?
Key Question #3: Why is EPS reported as N/A for every period, and what is the share count?

BDTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Black Diamond Therapeutics Inc. (BDTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BDTX Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 20h ago

Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX?

StockInvest.us report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 23h ago

BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview

ChartMill report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Black Diamond Therapeutics, Inc. (BDTX) Seasonal returns chart

Yahoo Finance UK report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Black Diamond Therapeutics(BDTX) Stock Options Chain | Quotes & News

Moomoo report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Simply Wall St report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Stoke Therapeutics, Inc. (STOK) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Black Diamond Therapeutics, Inc. (BDTX) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Black Diamond Therapeutics, Inc. Stock Price Today | BDTX Live Chart & News

Traders Union report covering Black Diamond Therapeutics Inc. (BDTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BDTX Bull vs. Bear Conversation Board — What's Your Call at $1.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BDTX 🐻 33% BEARISH CONVICTION

CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $2.28 (+28.1%)

📌 Pinned Debate

FY 2025 operating income turned positive at $12.5M and free cash flow reached $29.6M, a sharp reversal from prior-year losses.

Picked up a starter position in BDTX in my $100K Virtual Cash book at $1.78. FY 2025 operating income turned positive at $12.5M and free cash flow reached $29.6M, a sharp reversal from prior-year losses.. Trading inside a $1.60–$4.94 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@RiskArb_Desk Shorting a 5/20 institutional whale-flow stock at $1.78 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.48 (-16.9%)

Spot @ $1.78

The company reports zero revenue in every period while carrying a $106.9M market cap and an FCF yield of 0%.

Careful chasing BDTX at $1.78. The company reports zero revenue in every period while carrying a $106.9M market cap and an FCF yield of 0%.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.48 on multiple compression.